Module 3. Management and Treatment of MDS

How is higher-risk MDS treated?

MDS experts, Dr Alan List and Dr David Sallman, explain that the goals of therapy for patients with higher-risk myelodysplastic syndromes (MDS) are to improve symptoms, decrease the risk of leukemia, and improve survival. The primary treatment options for higher-risk MDS discussed are: hypomethylating agents (azacitidine and decitabine) and allogeneic stem cell transplant.
Please rate this content:
Animation - Management and Treatment of MDS
1. Animation - Management and Treatment of MDS
Slide Show - Management and Treatment of MDS
2. Slide Show - Management and Treatment of MDS

Expert Videos

What are the treatment options for MDS?
3. What are the treatment options for MDS?
How is lower-risk MDS treated?
4. How is lower-risk MDS treated?
How is higher-risk MDS treated?
5. How is higher-risk MDS treated?
What is supportive care for MDS?
6. What is supportive care for MDS?
Are vitamin supplements beneficial for MDS treatment?
7. Are vitamin supplements beneficial for MDS treatment?
What are erythropoietin-stimulating agents (ESAs)?
8. What are erythropoietin-stimulating agents (ESAs)?
What is cytotoxic chemotherapy and when is it used for MDS?
9. What is cytotoxic chemotherapy and when is it used for MDS?
What is lenalidomide and when is it used for MDS?
10. What is lenalidomide and when is it used for MDS?
What are hypomethylating agents and when are they used for MDS?
11. What are hypomethylating agents and when are they used for MDS?
How long will MDS treatment be given?
12. How long will MDS treatment be given?
What is immunosuppressive therapy and when is it used for MDS?
13. What is immunosuppressive therapy and when is it used for MDS?
What other options are there if first-line MDS treatment doesn’t work?
14. What other options are there if first-line MDS treatment doesn’t work?

Patient Videos

David's story: How was your MDS initially treated?
15. David's story: How was your MDS initially treated?

This educational activity has been developed by
the Myelodysplastic Syndromes Foundation, Inc and Mechanisms in Medicine Inc.

This activity is supported by charitable grants from Celgene Corporation, Jazz Pharmaceuticals, Novartis, and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their health care professionals for optimal outcomes.